NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week — Investor Reportedly Seeks Board Overhaul

Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge

Sector Update: Healthcare Stocks Softer Late Afternoon

Novartis stock in hot water after another key failure

Could Remibrutinib Become the Next $9 Billion Drug for Novartis?

BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)

This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree

Drug Trial Setbacks Raise Questions Over Novartis (NVS)’s Growth Pipeline

Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning

Novartis: More Pain on the Way?